Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

First-in-disease, Phase 2A multi-center, randomized, double-blind, placebo-controlled, crossover clinical trial to determine the potential efficacy, safety and pharmacokinetics of ES-481 in adult patients with drug resistant epilepsy. The study will consist of five periods.Participants will be randomly assigned to daily dosing of ES-481 or placebo based on the randomization scheme. The proposed starting oral dose of study medication in each treatment period is 25 mg qd in the morning and the proposed maximum dose is 75 mg bid.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ES Therapeutics Australia Pty Ltd

Criteria

Inclusion Criteria:

1. The subject/legal guardian must be able to understand and sign the Human Research Ethics Committee-approved written Informed Consent Form (ICF) and privacy language as per national regulations (e.g., HREC and TGA requirement in Australia) prior to any study-related procedures being performed

2. The subject is a male or female 18 to 65 years of age, inclusive

3. The subject must have a history of drug resistant epilepsy (as per the ILAE definition)

4. The subject must be taking 1 to 4 antiepileptic drugs (AED) and must be on a stable dose of the AEDs for at least four (4) weeks prior to entering the 28-day screening period

5. If VNS implanted, the stimulation setting must have been stable for at least four weeks prior to entering the 28-day screening period

6. The subject/legal guardian must be able to use the seizure dairy to record seizure throughout the study

7. The subject must experience at least four (4) countable seizures within a 28-day period.

For continued enrollment into Treatment Period 1, each subject will be confirmed to have experienced at least four (4) countable seizures in the 28-day screening period

8. The subject must have interictal epileptiform discharges and/or seizure with an average frequency of at least one (1) per hour on EEG recording.

For continued enrollment into Treatment Period 1, this will be confirmed by a 24-hour EEG performed during the 28-day screening period.

9. The subject is willing and able to comply with the study requirements

Exclusion Criteria:

1. Unwilling or inability to follow the procedures specified by the protocol

2. Pregnancy or breast feeding

3. Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:

Hormonal contraception (birth control pills, injected hormones or vaginal ring) Intrauterine device Barrier methods (condom or diaphragm) combined with spermicideSurgical sterilization (hysterectomy, tubal ligation, or vasectomy)

4. Current treatment for another significant medical disorder, such as diabetes, or heart disease or an untreated disorder, that is discovered during the 28-day screening period and might interfere with the study in the opinion of the Principal Investigator

5. An abnormality on clinical laboratory tests, physical examination, EEG or ECG that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR < 60 mL/min/1.73 m2

6. History (within the last year) of iilicit drug use or alcohol dependence

7. A level 4 or 5 on the Columbia Suicide Severity Rating Scale for symptoms during the last month prior to entering the 28-day screening period

8. Concomitant treatment with more than four (4) AEDs

9. Evidence for a potentially progressive neurologic disorder, such as a brain tumor, multiple sclerosis or dementia

10. Planned epilepsy surgery within six months of enrollment